Full Text Journal Articles by
Author Andrew Haydon

Advertisement

Find full text journal articles






Factors explaining socio-economic inequalities in survival from colon cancer: a causal mediation analysis.

Nina Afshar, S Ghazaleh Dashti, Luc Te Marvelde, Tony Blakely, Andrew Haydon, Victoria M White, Jon D Emery, Rebecca J Bergin, Kathryn Whitfield, Robert Js Thomas, Graham G Giles, Roger L Milne, Dallas R English,

<h4>Background</h4>Socio-economic inequalities in colon cancer survival exist in high-income countries, but the reasons are unclear. We assessed the mediating effects of stage at diagnosis, co-morbidities and treatment (surgery and intravenous chemotherapy) on survival from colon cancer.<h4>Methods</h4>We identified 2203 people aged 15-79 years with first primary colon cancer diagnosed in Victoria, ... Read more >>

Cancer Epidemiol Biomarkers Prev (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.

B Mark Smithers, Robyn P M Saw, David E Gyorki, Richard C W Martin, Victoria Atkinson, Andrew Haydon, Rachel Roberts-Thomson, John F Thompson,

Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care pathways for patients with melanoma. Accurate staging is critical to ensure a ... Read more >>

ANZ J Surg (ANZ journal of surgery)
[2021, 91 Suppl 2:3-13]

Cited: 0 times

View full text PDF listing >>



Advertisement

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

Adriana Hepner, Victoria G Atkinson, James Larkin, Rebecca A Burrell, Matteo S Carlino, Douglas B Johnson, Lisa Zimmer, Katy K Tsai, Oliver Klein, Serigne N Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V Long, Alexander M Menzies,

<h4>Purpose</h4>Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown.<h4>Methods</h4>Patients with advanced melanoma who initially achieved a complete ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 153:213-222]

Cited: 0 times

View full text PDF listing >>



Findings and Resolution of Melanoma Perineural Spread Along the Greater Auricular Nerve on FDG PET/CT and MRI.

Jennifer Nguyen, Thomas W Barber, Rhoda Cameron, Andrew Haydon, Victoria Mar,

<h4>Abstract</h4>We report an unusual case of a 59-year-old man with recurrent right ear melanoma resulting in perineural spread to the right greater auricular nerve. Direct perineural spread to the greater auricular nerve is not commonly reported in melanoma. Our case demonstrates perineural spread along the greater auricular nerve on 18F-FDG ... Read more >>

Clin Nucl Med (Clinical nuclear medicine)
[2021, 46(6):e329-e331]

Cited: 0 times

View full text PDF listing >>



Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.

Jeanne Tie, Yuxuan Wang, Joshua Cohen, Lu Li, Wei Hong, Michael Christie, Hui Li Wong, Suzanne Kosmider, Rachel Wong, Benjamin Thomson, Julian Choi, Adrian Fox, Kathryn Field, Matthew Burge, Jenny Shannon, Dusan Kotasek, Niall C Tebbutt, Christos Karapetis, Craig Underhill, Andrew Haydon, Joy Schaeffer, Janine Ptak, Cristian Tomasetti, Nicholas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Peter Gibbs,

<h4>Background</h4>In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal residual disease, is a powerful prognostic factor in patients with nonmetastatic colorectal cancer (CRC). Serial ... Read more >>

PLoS Med (PLoS medicine)
[2021, 18(5):e1003620]

Cited: 0 times

View full text PDF listing >>



Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, Alison M Weppler, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L Gerard, Olivier Michielin, Andrew Haydon, Paolo A Ascierto, Matteo S Carlino, Celeste Lebbe, Paul Lorigan, Douglas B Johnson, Shahneen Sandhu, Serigne N Lo, Christian U Blank, Alexander M Menzies, Georgina V Long,

<h4>Background</h4>Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determine the efficacy and safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) compared with ipilimumab monotherapy in ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(6):836-847]

Cited: 0 times

View full text PDF listing >>



Adapting pharmacy experiential education during COVID-19: Innovating remote preceptor resources, tools, and patient care delivery beyond virtual meetings.

Elaine Law, Marie C Scott, Yong S K Moon, Audrey J Lee, Veronica T Bandy, Andrew Haydon, Allen Shek, S Lena Kang-Birken,

<h4>Disclaimer</h4>In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version ... Read more >>

Am J Health Syst Pharm (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.

Oliver Klein, Wendy A Brown, Sarah Saxon, Andrew Haydon,

Perioperative chemotherapy is standard treatment for patients with early high-risk gastroesophageal adenocarcinoma independent of molecular subtype. Approximately 8% of gastroesophageal cancers have a microsatellite instable phenotype (MSI-H), and retrospective analyses of neoadjuvant/adjuvant chemotherapy trials suggests no survival benefit in this patient population compared with surgery alone. Patients with advanced MSI-H ... Read more >>

Oncologist (The oncologist)
[2021, 26(6):461-464]

Cited: 0 times

View full text PDF listing >>



Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study.

Harindra Jayasekara, Allison M Hodge, Andrew Haydon, Robin Room, John L Hopper, Dallas R English, Stephanie A Smith-Warner, Graham G Giles, Roger L Milne, Robert J MacInnis,

Alcohol consumption is a known cause of cancer, but its role in the etiology of second primary (metachronous) cancer is uncertain. Associations between alcohol intake up until study enrollment (prediagnosis) and risk of metachronous cancer were estimated using 9435 participants in the Melbourne Collaborative Cohort Study who were diagnosed with ... Read more >>

Int J Cancer (International journal of cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

Judith M Versluis, Anne M Hendriks, Alison M Weppler, Lauren J Brown, Karlijn de Joode, Karijn P M Suijkerbuijk, Lisa Zimmer, Ellen W Kapiteijn, Clara Allayous, Douglas B Johnson, Adriana Hepner, Joanna Mangana, Prachi Bhave, Yanina J L Jansen, Claudia Trojaniello, Victoria Atkinson, Lucy Storey, Paul Lorigan, Paolo A Ascierto, Bart Neyns, Andrew Haydon, Alexander M Menzies, Georgina V Long, Celeste Lebbe, Astrid A M van der Veldt, Matteo S Carlino, Shahneen Sandhu, Harm van Tinteren, Elisabeth G E de Vries, Christian U Blank, Mathilde Jalving,

<h4>Introduction</h4>In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma.<h4>Patients and methods</h4>Patients with metastatic melanoma treated with ICI between 2010 and 2019 ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 151:72-83]

Cited: 0 times

View full text PDF listing >>



Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

Lauren J Brown, Alison Weppler, Prachi Bhave, Clara Allayous, J Randall Patrinely, Patrick Ott, Shahneen Sandhu, Andrew Haydon, Celeste Lebbe, Douglas B Johnson, Georgina V Long, Alexander A Menzies, Matteo S Carlino,

<h4>Background</h4>Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combination therapy which has significantly higher toxicity risk. We sought to ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(5):]

Cited: 0 times

View full text PDF listing >>



Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.

J Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova, Hui Ling Yeoh, Marisa Palmeri, Fei Ye, Run Fan, Elizabeth J Davis, Suthee Rapisuwon, Georgina V Long, Andrew Haydon, Iman Osman, Janice M Mehnert, Matteo S Carlino, Ryan J Sullivan, Alexander M Menzies, Douglas B Johnson,

<h4>Importance</h4>Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not been well defined.<h4>Objective</h4>To determine the incidence, time ... Read more >>

JAMA Oncol (JAMA oncology)
[2021, 7(5):744-748]

Cited: 2 times

View full text PDF listing >>



Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, Susana Puig, Paolo A Ascierto, James Larkin, Paul C Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Alexander M M Eggermont, ,

<h4>Background</h4>The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.<h4>Methods</h4>This double-blind, ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):655-664]

Cited: 0 times

View full text PDF listing >>



Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, ,

<h4>Background</h4>The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43-0·74], p<0·0001) compared with placebo, leading to its approval in the USA ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):643-654]

Cited: 0 times

View full text PDF listing >>



Effect of Aspirin on Cancer Incidence and Mortality in Older Adults.

John J McNeil, Peter Gibbs, Suzanne G Orchard, Jessica E Lockery, Wendy B Bernstein, Yin Cao, Leslie Ford, Andrew Haydon, Brenda Kirpach, Finlay Macrae, Catriona McLean, Jeremy Millar, Anne M Murray, Mark R Nelson, Galina Polekhina, Christopher M Reid, Ellen Richmond, Luz Maria Rodríguez, Raj C Shah, Jeanne Tie, Asad Umar, G J van Londen, Kathlyn Ronaldson, Rory Wolfe, Robyn L Woods, John Zalcberg, Andrew T Chan, ,

<h4>Background</h4>ASPirin in Reducing Events in the Elderly, a randomized, double-blind, placebo-controlled trial of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, primarily due to cancer. In contrast, prior randomized controlled trials, mainly involving younger individuals, demonstrated a delayed cancer benefit with aspirin. We now report ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, 113(3):258-265]

Cited: 11 times

View full text PDF listing >>



Reduced melanoma referrals during COVID-19 lockdown.

William Berry, Katrina Tan, Andrew Haydon, Mark Shackleton, Victoria J Mar,

As the COVID-19 pandemic has reduced face-to-face medical consultations, reduced diagnoses of thin melanomas and delayed presentations of thick melanomas were anticipated. ... Read more >>

Aust J Gen Pract (Australian journal of general practice)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Diet and risk of gastro-oesophageal reflux disease in the Melbourne Collaborative Cohort Study.

Sabrina E Wang, Allison M Hodge, S Ghazaleh Dashti, Suzanne C Dixon-Suen, Hazel Mitchell, Robert Js Thomas, Elizabeth M Williamson, Enes Makalic, Alex Boussioutas, Andrew M Haydon, Graham G Giles, Roger L Milne, Bradley J Kendall, Dallas R English,

<h4>Objective</h4>To examine associations between diet and risk of developing gastro-oesophageal reflux disease (GERD).<h4>Design</h4>Prospective cohort with a median follow-up of 15·8 years. Baseline diet was measured using a FFQ. GERD was defined as self-reported current or history of daily heartburn or acid regurgitation beginning at least 2 years after baseline. Sex-specific ... Read more >>

Public Health Nutr (Public health nutrition)
[2021, :1-13]

Cited: 0 times

View full text PDF listing >>



Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies.

Harindra Jayasekara, Robert J MacInnis, Leila Lujan-Barroso, Ana-Lucia Mayen-Chacon, Amanda J Cross, Bengt Wallner, Domenico Palli, Fulvio Ricceri, Valeria Pala, Salvatore Panico, Rosario Tumino, Tilman Kühn, Rudolf Kaaks, Kostas Tsilidis, Maria-Jose Sánchez, Pilar Amiano, Eva Ardanaz, María Dolores Chirlaque López, Susana Merino, Joseph A Rothwell, Marie-Christine Boutron-Ruault, Gianluca Severi, Hanna Sternby, Emily Sonestedt, Bas Bueno-de-Mesquita, Heiner Boeing, Ruth Travis, Torkjel M Sandanger, Antonia Trichopoulou, Anna Karakatsani, Eleni Peppa, Anne Tjønneland, Yi Yang, Allison M Hodge, Hazel Mitchell, Andrew Haydon, Robin Room, John L Hopper, Elisabete Weiderpass, Marc J Gunter, Elio Riboli, Graham G Giles, Roger L Milne, Antonio Agudo, Dallas R English, Pietro Ferrari,

Alcohol consumption is causally linked to several cancers but the evidence for stomach cancer is inconclusive. In our study, the association between long-term alcohol intake and risk of stomach cancer and its subtypes was evaluated. We performed a pooled analysis of data collected at baseline from 491 714 participants in the ... Read more >>

Int J Cancer (International journal of cancer)
[2021, 148(11):2759-2773]

Cited: 0 times

View full text PDF listing >>



Reply to E. Hindié.

Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(8):944-946]

Cited: 0 times

View full text PDF listing >>



Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.

Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, Michelle Morris, Niall Tebbutt, Christine Aiken, Andrea Harkin, Eva Segelov, Andrew Haydon, Tim Iveson, Martin R Stockler,

<h4>Background</h4>SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients' preferences for 3 months vs 6 months of adjuvant chemotherapy in the SCOT trial.<h4>Methods</h4>SCOT participants from Australia and New Zealand completed a validated questionnaire ... Read more >>

JNCI Cancer Spectr (JNCI cancer spectrum)
[2021, 5(1):pkaa107]

Cited: 0 times

View full text PDF listing >>



Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.

Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel,

<h4>Background</h4>To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.<h4>Methods</h4>The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(2):]

Cited: 6 times

View full text PDF listing >>



Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

Prachi Bhave, Lalit Pallan, Georgina V Long, Alexander M Menzies, Victoria Atkinson, Justine V Cohen, Ryan J Sullivan, Vanna Chiarion-Sileni, Marta Nyakas, Katharina Kahler, Axel Hauschild, Ruth Plummer, Claudia Trojaniello, Paolo A Ascierto, Lisa Zimmer, Dirk Schadendorf, Clara Allayous, Celeste Lebbe, Andrea Maurichi, Mario Santinami, Severine Roy, Caroline Robert, Thierry Lesimple, Sapna Patel, Judith M Versluis, Christian U Blank, Adnan Khattak, Andre Van der Westhuizen, Matteo S Carlino, Mark Shackleton, Andrew Haydon,

<h4>Background</h4>Adjuvant targeted therapy (TT) improves relapse free survival in patients with resected BRAF mutant stage III melanoma. The outcomes and optimal management of patients who relapse after adjuvant TT is unknown.<h4>Methods</h4>Patients from twenty-one centres with recurrent melanoma after adjuvant TT were included. Disease characteristics, adjuvant therapy, recurrence, treatment at relapse ... Read more >>

Br J Cancer (British journal of cancer)
[2021, 124(3):574-580]

Cited: 0 times

View full text PDF listing >>



Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.

Jeanne Tie, Joshua D Cohen, Serigne N Lo, Yuxuan Wang, Lu Li, Michael Christie, Margaret Lee, Rachel Wong, Suzanne Kosmider, Iain Skinner, Hui Li Wong, Belinda Lee, Matthew E Burge, Desmond Yip, Christos S Karapetis, Timothy J Price, Niall C Tebbutt, Andrew M Haydon, Janine Ptak, Mary J Schaeffer, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Cristian Tomasetti, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Peter Gibbs,

Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined analysis of data across completed studies could further our understanding of circulating tumor DNA (ctDNA) as a prognostic marker and inform future trial design. We combined individual patient data from ... Read more >>

Int J Cancer (International journal of cancer)
[2021, 148(4):1014-1026]

Cited: 5 times

View full text PDF listing >>



Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic.

Craig Underhill, Phillip Parente, Grant McArthur, Andrew Haydon, Sue-Anne McLachlan, Zee Wan Wong, Eva Segelov, ,

In response to the COVID-19 pandemic, the Department of Health and Human Services Victoria (DHHS), the Monash Partners Comprehensive Cancer Consortium (MPCCC) and Victorian Comprehensive Cancer Centre (VCCC) pooled their combined infrastructure to establish the Victorian COVID-19 Cancer Network (VCCN) backed by a Taskforce of expert members. In a few ... Read more >>

Intern Med J (Internal medicine journal)
[2020, 50(10):1282-1285]

Cited: 0 times

View full text PDF listing >>



Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M Kirkwood, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V Long, Dirk Schadendorf,

<h4>Background</h4>In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with <i>BRAF</i> V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(12):1139-1148]

Cited: 15 times

View full text PDF listing >>



Advertisement

Disclaimer
1.244 s